published meta-analysis   sensitivity analysis   studies

SNG001 inhaled interferon beta in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSynairgen SG016, 2020 0.16 [0.01; 3.31] 0.16[0.01; 3.31]Synairgen SG016, 202010%101NAnot evaluable clinical deteriorationdetailed resultsSynairgen SG016, 2020 0.50 [0.18; 1.38] 0.50[0.18; 1.38]Synairgen SG016, 202010%101NAnot evaluable clinical improvementdetailed resultsSynairgen SG016, 2020 2.32 [1.07; 5.04] 2.32[1.07; 5.04]Synairgen SG016, 202010%NAnot evaluable clinical improvement (28-day)detailed resultsSynairgen SG016, 2020 3.15 [1.39; 7.14] 3.15[1.39; 7.14]Synairgen SG016, 202010%101NAnot evaluable death or ventilationdetailed resultsSynairgen SG016, 2020 0.38 [0.09; 1.63] 0.38[0.09; 1.63]Synairgen SG016, 202010%NAnot evaluable hospital dischargedetailed resultsSynairgen SG016, 2020 1.63 [0.61; 4.35] 1.63[0.61; 4.35]Synairgen SG016, 202010%101NAnot evaluable recoverydetailed resultsSynairgen SG016, 2020 2.19 [1.03; 4.67] 2.19[1.03; 4.67]Synairgen SG016, 202010%101NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 14:50 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 687 - roots T: 290